A new study has found that individuals who take statins may experience increased cortical thickness in certain regions of the brain, raising the possibility that these widely used cholesterol-lowering drugs could have protective effects against Alzheimer’s disease. Researchers examined data from nearly 850 older adults, including individuals with mild cognitive impairment and Alzheimer’s, to assess the relationship between statin use and brain structure. The findings were published in the journal Experimental Gerontology.
The study, which analysed MRI scans, found that statin users had greater cortical thickness compared to non-users across multiple brain regions. This effect was particularly noticeable in those with mild cognitive impairment, a condition often considered a precursor to Alzheimer’s. Among this group, statin use was associated with slower cortical thinning in a brain region linked to decision-making and emotional regulation. The findings suggest that statins might help preserve brain structure during early cognitive decline, although further research is needed to confirm their long-term impact on disease progression.
Statins are primarily prescribed to lower cholesterol levels and reduce the risk of cardiovascular diseases. Some types of statins can cross the blood-brain barrier, leading researchers to investigate their potential effects on neurological health. The role of cholesterol in brain function is complex, as it is essential for neuron stability and communication. However, imbalances in cholesterol metabolism have been linked to neurodegenerative conditions such as Alzheimer’s disease.
In this study, researchers classified participants as statin users if they had been taking the medication for at least two years. By examining cortical thickness, a key indicator of brain health, they found that statin use was associated with structural differences in regions known to be affected by Alzheimer’s. Healthy older adults who took statins showed greater cortical thickness in areas related to memory and visual processing, while those with mild cognitive impairment exhibited even more pronounced effects. However, among individuals already diagnosed with Alzheimer’s, the study found no significant differences in the rate of brain atrophy between statin users and non-users.
While the findings are promising, experts caution that they do not establish a direct cause-and-effect relationship between statin use and Alzheimer’s risk. The study highlights an association but does not confirm whether statins actively prevent neurodegeneration or if other factors are involved. Differences in lifestyle, diet, and overall health could also contribute to the observed brain structure variations. Additionally, not all statins function in the same way, with some more capable of entering the brain than others, which may influence their potential effects on cognitive health.
Previous research on the relationship between statins and dementia has yielded mixed results. Some studies have suggested that statins reduce the risk of developing Alzheimer’s, while others have found no significant impact. This latest study adds to the growing body of evidence suggesting that statins could play a role in brain health, particularly in the early stages of cognitive impairment.
Researchers emphasise the need for further studies to determine whether statins could be used as a potential intervention for Alzheimer’s prevention. Large-scale clinical trials with longer follow-up periods would help clarify whether these medications provide long-term cognitive benefits. Until then, individuals taking statins for cardiovascular health should continue their prescribed treatment while maintaining a healthy lifestyle to support brain function.
